The Ahmedabad-based Zydus Cadila Healthcare has bagged the global marketing rights of Vaxirab, an anti-rabies vaccine, from Swiss company Berna Biotech.
The drug will also be manufactured by Zydus Cadila Healthcare at a Rs 16 crore plant to be set up by the company on the outskirts of Ahmedabad.
The vaccine, which is currently licensed in 30 countries in Europe, south-east Asia and Latin America, was earlier being manufactured and marketed by Berna Biotech globally.
More From This Section
Berna Biotech, which has handed over Vaxirab to the Rs 1,100 crore Zydus Cadila under a technology transfer agreement, will also provide technical assistance to Zydus for setting up the plant.